Group 1 - The core point of the article is that Jiangyin Beirisen Biochemical Technology Co., Ltd. has successfully completed a new round of financing, led by Honghui Fund, with Luhua Investment participating, and Kunquan Capital serving as the financial advisor [1] - The funds from this financing round will primarily be used for the clinical development of biomedical materials based on mussel adhesive protein, specifically for Class III medical devices and chronic wound care products, enhancing Beirisen's competitive edge as a global original manufacturer of mussel adhesive protein [1] - Beirisen was established in 2011 and focuses on the development of macromolecular original raw materials centered on mussel adhesive protein, aiming for medical research, industrial development, and commercialization, thus forming a complete industry chain from laboratory to market [1] Group 2 - The company was co-founded by Dr. Gu Ming from the Chinese Academy of Sciences and Jan-Christer Janson, an internationally renowned expert in protein separation and purification, who received the 2015 International Science and Technology Cooperation Award of the People's Republic of China [1] - The company has appointed Nobel Prize winner Bengt Samuelsson as the chief scientist, indicating a strong emphasis on scientific expertise [1] - According to Tianyancha, the legal representative, chairman, and manager of Beirisen is Gu Ming, with a registered capital of 11.11 million yuan, and the top three shareholders are Gu Ming, Gao Min, and Jan Christer Janson, holding 67.54%, 7.02%, and 5.85% of the shares respectively [4]